BEHRENS M KATHLEEN 4

What Happened
Kathleen M. Behrens, a director of Sarepta Therapeutics (SRPT), was granted 16,875 restricted stock units (RSUs) on 2026-06-04. Each RSU represents the right to receive one share of Sarepta common stock upon vesting. No per-share price or immediate cash value was reported (price = N/A); this is a grant/award (transaction code A), not an open-market buy or sale.

Key Details

• Transaction date: 2026-06-04 (Form 4 filed 2026-06-05 — timely filing).
• Grant: 16,875 RSUs; price reported as N/A (typical for awards).
• Vesting: RSUs vest on the earlier of the one-year anniversary of grant or the next annual meeting of stockholders that is at least 50 weeks after the prior meeting (per footnote).
• Shares owned after transaction: not specified in the Form 4 filing.
• Transaction type: Award/Grant (A); not a purchase or sale and not an exercise.

Context
RSUs are a common form of director compensation and convert to shares only after vesting; they are not immediately tradable and do not necessarily indicate the director is buying or selling stock. This grant is routine equity compensation rather than an express market sentiment signal.